Earnshaw S - Search Results

1

Cardiovascular Genetic Risk Testing for Targeting Statin Therapy in the Primary Prevention of Atherosclerotic Cardiovascular Disease: A Cost-Effectiveness Analysis.

Jarmul J, Pletcher MJ, Hassmiller Lich K, Wheeler SB, Weinberger M, Avery CL, Jonas DE, Earnshaw S, Pignone M. Jarmul J, et al. Among authors: earnshaw s. Circ Cardiovasc Qual Outcomes. 2018 Apr;11(4):e004171. doi: 10.1161/CIRCOUTCOMES.117.004171. Circ Cardiovasc Qual Outcomes. 2018. PMID: 29650716

2

Aspirin, statins, or both drugs for the primary prevention of coronary heart disease events in men: a cost-utility analysis.

Pignone M, Earnshaw S, Tice JA, Pletcher MJ. Pignone M, et al. Among authors: earnshaw s. Ann Intern Med. 2006 Mar 7;144(5):326-36. doi: 10.7326/0003-4819-144-5-200603070-00007. Ann Intern Med. 2006. PMID: 16520473

3

Aspirin for the primary prevention of cardiovascular disease in women: a cost-utility analysis.

Pignone M, Earnshaw S, Pletcher MJ, Tice JA. Pignone M, et al. Among authors: earnshaw s. Arch Intern Med. 2007 Feb 12;167(3):290-5. doi: 10.1001/archinte.167.3.290. Arch Intern Med. 2007. PMID: 17296886

4

Cost-utility of aspirin and proton pump inhibitors for primary prevention.

Earnshaw SR, Scheiman J, Fendrick AM, McDade C, Pignone M. Earnshaw SR, et al. Arch Intern Med. 2011 Feb 14;171(3):218-25. doi: 10.1001/archinternmed.2010.525. Arch Intern Med. 2011. PMID: 21325111 Free PMC article.

5

Effect of including cancer mortality on the cost-effectiveness of aspirin for primary prevention in men.

Pignone M, Earnshaw S, McDade C, Pletcher MJ. Pignone M, et al. Among authors: earnshaw s. J Gen Intern Med. 2013 Nov;28(11):1483-91. doi: 10.1007/s11606-013-2465-6. Epub 2013 May 17. J Gen Intern Med. 2013. PMID: 23681842 Free PMC article.

6

Using the coronary artery calcium score to guide statin therapy: a cost-effectiveness analysis.

Pletcher MJ, Pignone M, Earnshaw S, McDade C, Phillips KA, Auer R, Zablotska L, Greenland P. Pletcher MJ, et al. Among authors: earnshaw s. Circ Cardiovasc Qual Outcomes. 2014 Mar;7(2):276-84. doi: 10.1161/CIRCOUTCOMES.113.000799. Epub 2014 Mar 11. Circ Cardiovasc Qual Outcomes. 2014. PMID: 24619318 Free PMC article.

7

Cost-effectiveness of Maintaining Daily Intake of Oat β-Glucan for Coronary Heart Disease Primary Prevention.

Earnshaw SR, McDade CL, Chu Y, Fleige LE, Sievenpiper JL. Earnshaw SR, et al. Clin Ther. 2017 Apr;39(4):804-818.e3. doi: 10.1016/j.clinthera.2017.02.012. Epub 2017 Mar 25. Clin Ther. 2017. PMID: 28347513 Free article.

8

Cost effectiveness of 5-alpha reductase inhibitors for the prevention of prostate cancer in multiple patient populations.

Earnshaw SR, McDade CL, Black LK, Bell CF, Kattan MW. Earnshaw SR, et al. Pharmacoeconomics. 2010;28(6):489-505. doi: 10.2165/11531780-000000000-00000. Pharmacoeconomics. 2010. PMID: 20196623

9

Cost-effectiveness of pegaptanib compared to photodynamic therapy with verteporfin and to standard care in the treatment of subfoveal wet age-related macular degeneration in Canada.

Earnshaw SR, Moride Y, Rochon S. Earnshaw SR, et al. Clin Ther. 2007 Sep;29(9):2096-106; discussion 2094-5. doi: 10.1016/j.clinthera.2007.09.001. Clin Ther. 2007. PMID: 18035208

10

Cost-effectiveness model for neovascular age-related macular degeneration: comparing early and late treatment with pegaptanib sodium based on visual acuity.

Javitt JC, Zlateva GP, Earnshaw SR, Pleil AM, Graham CN, Brogan AJ, Shah SN, Adamis AP. Javitt JC, et al. Value Health. 2008 Jul-Aug;11(4):563-74. doi: 10.1111/j.1524-4733.2007.00283.x. Epub 2007 Dec 17. Value Health. 2008. PMID: 18179676 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

70 results

Search Page

Filters